Revolution Medicines (RVMD) Equity Average (2019 - 2026)

Revolution Medicines has reported Equity Average for 8 years, with the latest figure at $1.6 billion in Q1 2026.

• For the quarter ending Q1 2026, Equity Average fell 27.91% year-over-year to $1.6 billion; the trailing twelve-month figure through Mar 2026 stood at $1.6 billion (down 27.91% YoY), and the FY2025 full-year result was $1.9 billion, down 4.76% from the prior year.
• Equity Average for Q1 2026 stood at $1.6 billion, down from $1.6 billion in the prior quarter.
• The five-year high for Equity Average was $2.2 billion in Q1 2025, with the low at $524.9 million in Q2 2022.
• Average Equity Average over 5 years is $1.3 billion, with a median of $1.6 billion recorded in 2026.
• Year-over-year, Equity Average jumped 116.91% in 2024 and slipped 27.91% in 2026.
• Tracing RVMD's Equity Average over 5 years: stood at $683.3 million in 2022, then soared by 94.91% to $1.3 billion in 2023, then surged by 43.84% to $1.9 billion in 2024, then fell by 15.75% to $1.6 billion in 2025, then retreated by 3.0% to $1.6 billion in 2026.
• The last three Equity Average figures came in at $1.6 billion (Q1 2026), $1.6 billion (Q4 2025), and $1.7 billion (Q3 2025), per Business Quant data.

Peer Comparison